News and Updates

March 2017

NovaTarg is approved for a $250,000 loan from the NC Biotech Center

February 2017

NT1195 is selected as a drug candidate for the treatment of Type 2 Diabetes in patients with impaired renal function. IND-enabling studies begin.

September 2015

NovaTarg has received $3.2 million in SBIR grant funding to further its discovery of tissue selective AMPK activators. NovaTarg plans to progress drug candidates for polycystic Kidney Disease and Type 2 Diabetes during this coming year.

June 2015

Ken Batchelor interviewed for an article about NovaTarg’s drug discovery activities in CEO:CFO Magazine.

June 2015

Dr Victoria Bae-Jump, MD, PhD, (UNC) has┬áreceived a Collaborative Funding Grant (CFG) from the North Carolina Biotech Center (NCBC) to support research on NovaTarg’s AMPK activators as potential treatments for ovarian cancer.

Feb 2015

NovaTarg, Inc receives $50,000 as a matching grant from the NC Dept of Commerce for discovery of a new drug for hepatocellular carcinoma (HCC) – the most common type of liver cancer and the third leading cause of cancer deaths worldwide.

Jan 2015

NovaTarg has filed 2 provisional patents to protect the intellectual property associated with our lead AMPK activators for metabolic disease, cancer and viral diseases.

Sept 2014

NovaTarg has received Phase 1 SBIR funding for its liver cancer project – ‘Novel and Selective AMPK Activators for the Treatment of Hepatocellular Carcinoma’. This funding will allow us to fully demonstrate the potential for our approach to deliver efficacy for malignant indications.

Feb 2014

NovaTarg has been awarded a Phase 2 SBIR grant to extend its studies on AMPK activators for type 2 diabetes (T2D). This grant will run for a 2 year period in a collaboration with Zen-Bio which is planned to culminate in the discovery of a new medicine to treat T2D.

Sept 2013

NovaTarg receives 2 SBIR Phase 1 grants to progress tissue selective AMPK activators for the treatment of type 2 diabetes and polycystic kidney disease

Mar 2012

NovaTarg outlines patent covering a tissue selective AMPK activator

Feb 2012

NovaTarg Therapeutics featured in Startup magazine

Jan 2012

Dr Nick Livingston and Dr Jeff Cobb join NovaTarg Therapeutics

Dec 2011

NovaTarg receives a $30K loan from the NC Biotech Center

Aug 2011

Successful Phase 1 SBIR application to support work on type 2 diabetes program

Oct 2010

Three Qualified Therapeutic Discovery Program grants awarded to NovaTarg. Total value of this award is $712,000

Oct 2009

NovaTarg Inc founded by Ken Batchelor with the intention of discovering innovative drugs for the treatment of metabolic diseases and cancer